Erika Ferrari, Commercial Science Leader, BiomimX Srl<\/em><\/p>\n Beating Organs-on-Chip are in vitro miniaturized models developed within the uBeat\u00ae platform, which integrates microfluidics, 3D human cell culture and controlled mechanical stimulation to recapitulate,
\nwith unprecedented precision and predictability, clinically relevant models reflective of human pathophysiology and complex diseases. Every tissue in the body is subject motion and this motion can be mimicked within the uBeat\u00ae platformplatforms, which provides 3D microtissues with controlled mechanical stimulation (e.g., stretching or compression) resulting in more reliable, responsive, and predictive in vitro model models to investigate new therapies. BiomimX lead model is uHeart Visone, Tox Sciences, 2023; +4 additional cardiac publications ), a functional beating heart on a chip for cardiotoxicity and safety testing. uHeart was recently qualified with 12 drugs as a predictor of functional cardiotoxicity, showing 83.3% sensitivity, 100% specificity, a nd 91.6% accuracy. BiomimX pipeline consists of predictive physiological and pathological models, engineered solely through mechanical stimulation, without the need for introducing exogenous compounds (e.g., cytokines) into the cell culture chamber. uKnee the first in vitro model of human osteoarthritis; Occhetta, Nature Biomed Eng, 2019 ) has successfully supported a recent IND application. Other key models include uScar cardiac fibrosis; Visone, Adv Healthcare Mat, 202 2023), uGut a barrier model of the intestinal epithelium & endothelium; Ballerini, Nature Biomed Eng, under review ), uLung and uLiver Heart a multiorgan platform used to study the off-target cardiotoxicity of liver-metabolized drugs; Ferrari, Adv Mat Tech, 2023 ).<\/p>\n","protected":false},"excerpt":{"rendered":"